s.grimaldi

TL2 · Salvador

Contributes reviews on supplier material. Based in Salvador.

Joined 22 November 2024 · last posted 23h

95Posts here

3Topics

1Solutions

193Likes received

173Likes given

20Badges

97Days visited

1.1kPosts read

Recent activity

Full stream

Risk-of-bias tools and the judgement they conceal — does this still hold? Replied, post #31 · Evidence › Meta-analyses · 27 Jul 2026 · 0 likes Counterpoint on Risk-of-bias tools, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
Distinguishing a red flag from an inconvenience — a second dataset Replied, post #8 · Sourcing › Red flags · 23 Jul 2026 · 0 likes Answering the question post #4 raises rather than the one it answers. Testimonials without a lot, a date, a method or a service are not evidence and are not a red flag…
Journal club: what we got wrong in an earlier session Replied, post #102 · Evidence › Journal club · 20 Jul 2026 · 15 likes That is the distinction I keep failing to hold on to. Written down now.
Insomnia at a dose step: reported experiences — the long version Replied, post #47 · Wellbeing › Sleep · 15 Jul 2026 · 26 likes What I want from this Insomnia thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it.
Coming back to: Batch date after test date, and other internal inconsistencies Replied, post #13 · Analytics › COA interpretation · 15 Jul 2026 · 2 likes Since Batch date keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience…
Here for the analytics and not much else Replied, post #20 · Lounge › Introductions · 11 Jul 2026 · 1 like Nice to meet you. Say what you are interested in rather than what you do, if you would rather — plenty of people here are anonymous about their background and it costs…
Endotoxin and why it is a separate question from purity — what changed since Replied, post #73 · Analytics › Impurities & related substances · 10 Jul 2026 · 14 likes Clear enough that I do not think I have a follow-up, which is unusual.
What a regulator's shortage notice actually authorises Replied, post #5 · Sourcing › Regulatory · 7 Jul 2026 · 16 likes Where a regulator publishes a decision summary, that document usually contains the reasoning and is far more informative than the announcement.
GLP-1 receptor distribution: central and peripheral Replied, post #83 · Pharmacology › Receptor biology · 4 Jul 2026 · 11 likes GLP-1 receptor distribution would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
Prescription requirements and telehealth models — a second dataset Replied, post #76 · Sourcing › Regulatory · 23 Jun 2026 · 31 likes On Prescription requirements and telehealth models, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the…
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Replied, post #72 · Compounds › Semaglutide · 21 Jun 2026 · 1 like Post #70 is the version of this I will quote in future. One addition. Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible…
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #7 · marked as the solution · Compounds › Retatrutide · 17 Jun 2026 · 7 likes Triple agonism at GLP-1, GIP and glucagon receptors is the defining feature and the glucagon limb is the one people find counter-intuitive. It raises energy expenditure…